Actinogen Medical
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Actinogen announces further positive results on depression in the XanCIDD phase 2a trial 2024-08-26 20:30
Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial 2024-08-12 20:30
Positive Xanamem® biomarker trial published in the Journal of Alzheimer's Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau 2024-06-26 20:56
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial 2024-04-22 20:30
First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial 2024-04-15 20:30
Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy 2024-01-24 21:30
Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024 2023-11-28 22:00
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston 2023-10-13 20:00
Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update 2023-09-26 20:51
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention 2023-05-31 20:58
Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference 2023-03-30 21:00
FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial 2022-12-22 20:30
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial 2022-12-14 21:52
Actinogen Medical Limited (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer's Disease (AD) patients 2022-10-10 20:00
1